Nerandomilast slows lung function decline in IPF, PPF Clinical trials

Nerandomilast slows lung function decline in IPF, PPF Clinical trials

Nerandomilast, Boehringer Ingelheim’s investigational oral therapy, significantly slowed lung function decline in people with idiopathic pulmonary…

Continue Reading
Nerandomilast Slows Lung Function Decline in Patients With IPF

Nerandomilast Slows Lung Function Decline in Patients With IPF

Nerandomilast (BI 1015550; Boehringer Ingelheim), an oral phosphodiesterase 4B (PDE4B) inhibitor, significantly slowed lung function decline…

Continue Reading
Nerandomilast Improves Lung Function in Progressive Pulmonary Fibrosis: FIBRONEER-ILD

Nerandomilast Improves Lung Function in Progressive Pulmonary Fibrosis: FIBRONEER-ILD

Nerandomilast met its primary end point of absolute change from baseline in forced vital capacity (FVC)…

Continue Reading